Comac Medical

Comac Medical

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Comac Medical is a private, revenue-generating, full-service CRO headquartered in Sofia, Bulgaria, with approximately 350 employees. It provides end-to-end clinical trial services across all phases and therapeutic areas, with a strong geographic focus on Central/Eastern Europe and Eurasia. A key strategic move is its recent unification with ILIFE Consulting, enhancing its early-phase and oncology capabilities. The company differentiates itself through owned early-phase units, a bioanalytical lab, and a focus on patient recruitment speed in diverse populations.

OncologyCardiologyCNSDermatologyGastroenterologyHematologyImmunologyInfectious DiseasesMetabolic DiseasesMusculoskeletal DiseasesNephrologyObstetrics & GynecologyOphthalmologyRare Diseases

Technology Platform

Integrated CRO service platform featuring a fully owned Early Phase Unit with co-located bioanalytical lab, and an extensive geographic network across Europe and Eurasia for patient recruitment and site management.

Pipeline

4
4 drugs in pipeline1 in Phase 3
DrugIndicationStageWatch
VaccineInfluenzaPhase 3
GB1211 + PlaceboHepatic ImpairmentPhase 1/2
CHF6467 activeDiabetic Neuropathic Foot UlcersPhase 1/2
Influenza vaccine, split inactivatedInfluenza, HumanPhase 1

Opportunities

Capitalizing on the trend of clinical trial decentralization into Central/Eastern Europe and Eurasia for faster, cost-effective patient recruitment.
Leveraging the merger with ILIFE to capture more high-value, complex early-phase and oncology trials from biotech sponsors.

Risk Factors

Intense competition from both large global CROs and niche boutique firms.
Execution risks associated with integrating the ILIFE Consulting merger, including cultural and operational alignment.
Dependence on political and regulatory stability across its diverse geographic footprint.

Competitive Landscape

Operates in the highly competitive global CRO market, competing against large full-service players (e.g., IQVIA, ICON) and smaller specialized boutiques. Differentiates through a mid-sized, flexible partnership model, owned early-phase infrastructure, and deep regional expertise in Central/Eastern Europe and Eurasia.